Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disease and Osteoporosis Development.
TarMart Solution Ecosystem & Related Targets
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CALCR ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed for native glycosylation. |
View CALCR Products |
| Gene Delivery | CALCR Promise-ORF / Lentivirus Premade Particles Full-length human CALCR ORF for stable cell line construction. Preserve native conformation in mammalian cells. |
View CALCR Products |
| Benchmark Ligand | Calcitonin (CALCA) Peptide High purity positive control for receptor activation assays. |
View CALCA Products |
| Benchmark Antibody | Anti-CALCR (Sequence-matched Biosimilar Frame) Recombinant monoclonal reference for assay calibration. |
View CALCR Products |
| Validator | CALCR siRNA Set Validated knockdown sequences for specificity control in cell-based assays. |
View CALCR Products |
| RAMP Co-expression | RAMP1/RAMP2 Lentivirus For AMY1/AMY2 receptor complex assembly with CALCR. |
View RAMP1 Products |
| Related Target: RAMP1 | Receptor Activity Modifying Protein 1 Forms the AMY1 amylin receptor with CALCR; essential for metabolic pathway screening. |
View RAMP1 Products |
| Related Target: RAMP2 | Co-receptor forming the Amylin AMY2 receptor complex with CALCR. | View RAMP2 Products |
| Related Target: CALCRL | Calcitonin Receptor-Like Receptor Class B GPCR paralog; critical for CGRP counter-screening and selectivity panels. |
View CALCRL Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Full-length conformational integrity for Class B GPCR assays | Lentivirus-mediated stable expression in HEK293; preserves 7-TM topology and post-translational modification patterns. |
| RAMP-complex selectivity (AMY1 vs CALCR homodimer) | Modular Lentivirus system: CALCR + RAMP1/2/3 co-transduction; sequence-verified human and cyno orthologs available. |
| Cross-species peptide pharmacokinetics (cyno/mouse) | Human/Cynomolgus/Mouse CALCR ECD proteins with >95% purity; matched glycosylation profiles via HEK293 expression. |
| Homolog Selectivity (CALCR vs CALCRL) | Strictly purified ECD-Fc constructs with Mass Spec verification; distinct epitope availability for discrimination between Class B GPCR subfamily members. |
| Internalization Kinetics for ADC | Full-length Lentivirus-stable cell lines preserving endocytic machinery; suitable for pH-sensitive dye uptake assays and cAMP signaling correlation. |
| Off-Target Pathway Activation / False Positives | Validated siRNA included for specificity checks; CALCR knockdown confirmation eliminates non-specific compound interference. |
| High-concentration subcutaneous formulation stability | Aggregation-resistant assay buffer compatible; thermostability validation framework for peptide-receptor complexes. |
Live CALCR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic focus for CALCR is undergoing a paradigm shift from osteoporosis management toward metabolic disease intervention. While traditional calcitonin therapies faced safety challenges regarding medullary thyroid carcinoma (MTC) risk, the emergence of amylin receptor agonism—utilizing CALCR in complex with RAMP proteins—has revitalized the target. Major players (Novo Nordisk, Zealand Pharma) are now engineering long-acting peptide analogs (hybrid amylin/calcitonin mimetics, DACRAs) for obesity and type 2 diabetes, often in combination with GLP-1/GIP receptor agonists. As first-generation therapies reach the clinic, the next wave of R&D is targeting biased signaling profiles and long-acting subcutaneous formulations to improve metabolic efficacy and patient adherence. Concurrently, CALCR's high expression in MTC maintains its relevance as a diagnostic and potential ADC target in oncology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Peptide Agonists / Amylin Analogs | Novo Nordisk (Cagrilintide), Zealand Pharma, Amylin Pharma legacy assets | Obesity, Type 2 Diabetes | Cell-based cAMP/Ca2+ flux assay (Need full-length CALCR lentivirus with RAMP1 co-expression) |
| Dual Amylin/Calcitonin R Agonists (DACRA) | Novo Nordisk, Zealand Pharma | Obesity, Metabolic Syndrome | Bias signaling panel (Need G protein vs β-arrestin readouts on CALCR vs AMY1 complexes) |
| Long-Acting Calcitonin | Biosimilar developers, legacy pharma (Novartis, Generic Mfrs) | Osteoporosis, Hypercalcemia, Paget's Disease | Binding affinity & PK bridging (Need cross-reactive ECD-Fc for SPR/BLI across species) |
| Small Molecule Modulators | Early-stage biotech, Academic | Metabolic Disease, Chronic Pain | Orthosteric/allosteric screening (Need high-purity CALCR ECD and stable full-length cell lines) |
| ADC | Emerging Biotech (Preclinical) | Medullary Thyroid Carcinoma (MTC) | Internalization Assay (Need full-length CALCR stable cells with native trafficking) |
| Diagnostic Radiotracers | Diagnostic Imaging Companies | MTC Staging | High-purity ECD Protein (For tracer specificity validation vs CALCRL) |